Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company at the forefront of advancing cell therapies for cancer and autoimmune diseases. Utilizing adult stem cells, specifically induced pluripotent stem cells (iPSCs), Century Therapeutics leverages its proprietary Allo-Evasion™ technology to develop curative therapies that overcome the limitations of first-generation cell therapies.
The company's innovative platform integrates several advanced technologies including CRISPR-mediated gene editing, proprietary chimeric antigen receptors (CARs), and cutting-edge manufacturing capabilities. These combined elements enhance cell product performance, prevent host immune system rejection, and minimize development risks, positioning Century Therapeutics as a leader in the biotech sector.
Key Candidates and Achievements
- CNTY-101: An investigational CD19-targeting iPSC-derived natural killer (NK) cell therapy, CNTY-101 is designed for treating relapsed or refractory non-Hodgkin lymphoma (NHL). This product incorporates six precision gene edits and has shown promising early response signals, including complete and partial responses in clinical trials.
- Allo-Evasion™ Technology: Core to Century's strategy, this technology enables repeat dosing without the need for continual lymphodepletion, significantly improving patient outcomes. The company presented comprehensive data demonstrating the protective capabilities of its Allo-Evasion™ edits at major scientific conferences.
- Dual-Targeting CARs: Century has developed a novel CD19xCD22 bispecific CAR, demonstrating effective cytotoxicity against tumors in preclinical models, further expanding the potential applications of its therapies.
Recent News and Developments
- Clinical Trial Success: The ELiPSE-1 Phase 1 trial showcased encouraging initial data for CNTY-101, revealing its potential in treating aggressive B-cell lymphomas.
- New Partnerships and Acquisitions: The acquisition of Clade Therapeutics, a leader in iPSC-derived αβ T cells, enhances Century's pipeline, technology, and expertise in the cell therapy space.
- Financial Growth: Century recently secured $60 million in private placement funding, underscoring investor confidence in its strategic direction and potential market impact.
- Research Expansion: The company is expanding its clinical development into autoimmune disease indications, with a focus on leveraging its iPSC platform to address significant unmet medical needs.
For more detailed information about Century Therapeutics and its groundbreaking work in cell therapy, visit www.centurytx.com.
Century Therapeutics (NASDAQ: IPSC), a biotech company focused on developing iPSC-derived cell therapies for immuno-oncology and autoimmune disease, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Brent Pfeiffenberger and CSO Chad Cowan will engage in a fireside chat on November 12, 2024, at 9:30am ET. The presentation will be accessible via live webcast on the company's investor relations website, with replay available for 90 days post-event.
Century Therapeutics (NASDAQ: IPSC) has announced key leadership changes, effective October 2024. Morgan Conn, Ph.D., has been appointed as Chief Financial Officer, bringing over 20 years of financing and business development experience in biopharma. Chad Cowan, Ph.D., a cell therapy pioneer and founder of Clade Therapeutics, will serve as Chief Scientific Officer. Both will join the Executive Committee.
The company also announced that Hy Levitsky, M.D., President of Research and Development, will transition to an advisory role. These appointments come at a important time as Century advances its clinical programs, expands into autoimmune indications, and accelerates prioritized next-generation pipeline programs.
Century Therapeutics specializes in developing induced pluripotent stem cell (iPSC)-derived cell therapies for immuno-oncology and autoimmune diseases. The company's focus includes iNK, γδ iT, and αβ iT-cell programs, combined with its Allo-Evasion™ technology.
Century Therapeutics (NASDAQ: IPSC) reported Q2 2024 financial results and business updates. Key highlights include:
1. Initiation of Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, expanding into autoimmune diseases.
2. Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101, showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas.
3. Completed dose escalation for ELiPSE-1, advancing to dose expansion in 2H 2024.
4. Q2 2024 ended with $269.6 million in cash, cash equivalents, and investments.
5. Net loss of $31.2 million for Q2 2024.
6. Full-year GAAP operating expenses expected between $150-160 million.
7. Cash runway extended into 2026.
Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study at the ASCO 2024 Annual Meeting. The study evaluates CNTY-101, an iPSC-derived NK cell therapy, in patients with relapsed or refractory non-Hodgkin lymphoma. CNTY-101 demonstrated a manageable safety profile with no dose-limiting toxicities or graft-versus-host disease and showed encouraging preliminary efficacy. The trial's novel cell-free DNA method indicates CNTY-101 persists outside the bloodstream. The study continues with dose escalation at higher levels, aiming to further validate safety and efficacy.
Century Therapeutics presented preclinical data at the ASGCT Annual Meeting, showcasing advancements in their iPSC platform technology and programs. The data highlighted the potential of their lead candidate, CNTY-101, in treating B-cell driven autoimmune diseases like SLE. Additionally, the company introduced a novel synthetic ligand targeting CD300a to prevent NK mediated rejection in allogeneic cell therapies. These developments aim to enhance the efficacy, durability, and tolerability of their iPSC candidates, offering promising treatment options across various indications.
Century Therapeutics reported its first quarter 2024 financial results, with plans to expand into additional autoimmune disease indications beyond SLE with their iPSC derived NK cell therapy, CNTY-101. They closed a $60 million private placement, acquired Clade Therapeutics to enhance their platform, and provided additional clinical data. The company ended the quarter with $249.9 million in cash, cash equivalents, and investments, with a cash runway into 2026.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
What is Century Therapeutics' primary focus?
What is CNTY-101?
How does Century Therapeutics' Allo-Evasion™ technology work?
What recent achievements has Century Therapeutics made?
What are the potential applications of Century's dual-targeting CARs?
What are Century Therapeutics' plans for autoimmune diseases?
How does Century Therapeutics ensure the safety of its cell therapies?
What financial milestones has Century Therapeutics recently achieved?
Where can I find more information about Century Therapeutics?
What partnerships does Century Therapeutics have?
